

EVENT SPONSORSHIP AGREEMENT

This sponsorship agreement (“**Agreement**”) is effective as of the 23 October 2025 (“**Effective Date**”) and is entered by and between:

BeOne Medicines International GmbH Denmark Branch a company incorporated under the laws of Denmark whose registered office is c/o TMF Denmark, Købmagergade 60, DK-1150, Copenhagen K, Denmark (“**Company**”)

And

Patientforeningen Lungekræft a non-for-profit institution incorporated under the laws of Denmark whose registered office is at Møllehaven 8, 4040 Jyllinge, Denmark (“**Recipient**”)

WHEREAS, Company is a biotechnology company that develops and commercializes biopharmaceutical products;

WHEREAS Recipient is a non-for profit or profit organization that wish to organize the event described in Article 1 of the Agreement and has requested funding support.

WHEREAS Company after receiving Recipient request, which is attached as annex 1, has agreed to provide support to the Event as described below.

NOW THEREFORE in connection therewith and in consideration thereof, Recipient and Company agree as follows:

1. Company will provide Recipient with thirty-five thousand (35 000) DKK (“**Support**”) which shall be used by Recipient for the event described in this Article 1 (“**Event**”) and Company will receive the sponsorship benefits described in this Article 1.

Event Details

Title of Event: International Lungekraeft dag

Date of Event: 17 November 2025

Location of Event: Copenhagen

Agenda of the Event is attached as annex 2 to this Agreement

Sponsorship Benefits

Company will be entitled to the following sponsorship benefits:

- 2 representatives
- Logo in the programme

CONFIDENTIAL

2. Payment of the Support shall be made by Company to the bank account of Recipient identified on the invoice received from Recipient within sixty (60) days. The invoices must display any applicable VAT amount separately.
3. Recipient shall transparently disclose that Company has provided Support for the Event. Company shall have the right to publish the name of Recipient and the details of the Support and Event in order to comply with transparency reporting requirements. Such reporting may include the name of any relevant healthcare professional (HCP) who was a presenter at the Event and was paid at fair market value for his or her contribution to the Event.
4. Company shall have no control or influence over the content of the Event. Company does not agree, recommend, obtain or otherwise provide any details of the attendees that will participate in the Event.
5. The Parties agree that the sponsorship is not being provided by Company, nor accepted by Recipient, as an inducement to, either now or in the future, purchase, prescribe, promote, or recommend any of Company's products or services.
6. No part of the Support may be paid to any third party, other than as reasonable fair market value compensation for items and services obtained at fair market value provided to Recipient in connection with the Event in accordance with applicable laws, regulations and applicable industry codes of practice (including those pertaining to transparency reporting).
7. No portion of the Support shall be used by the Recipient to provide unlawful benefits to a healthcare professional or to any government employee or official. The Recipient represents and warrants that no person or company working on behalf of the Recipient, shall directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any person or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any applicable laws, rules and regulations concerning or relating to public or commercial bribery or corruption.
Recipient agrees to comply with all the regulations relating to Anti-Bribery, including the United States Foreign Corrupt Practices Act, as amended from time to time, with regard to the Event including not offering or giving anything of value to a foreign public official in connection with the performance of the official's duties or inducing an official to use their position to influence any acts or decisions of any foreign, state or public international organization.
Additionally, Recipient agrees to comply with the UK Antibribery Act.
8. The Recipient is free to seek funding from other companies. If any additional funding reaches a level such that all or part of the Support is no longer required by the Recipient, the Recipient shall refund such amount of the Support that is no longer required. Recipient shall return any unused funds provided by Company or any amounts not used in accordance with the terms and conditions of this Agreement:
 - within 30 days from the date of the Event or;
 - within 30 days from the cancellation of the Event or;


- within 30 days from termination by Company of the Agreement for Recipient breach of the obligations contained in the Agreement.
9. Any discussion of medicinal therapies or test/quizzes/votes concerning Continuing Professional Development (CPD) at the Event shall be non-promotional, balanced, accurate and complete and shall comply with applicable laws and regulations
 10. Recipient confirms that the selection of the location and timing of the Event is based on one of the following criteria: (i) the majority of the attendees are resident in the country where the Event will take place, or (ii) the attendees at the Event are coming from different countries and, therefore, the Event was selected based on logistical convenience considering the country of residence of the attendees.
 11. In the event Recipient becomes aware of an adverse event and/or a product complaint, Recipient shall inform Company's Safety Operations Group within 24 hours of first becoming aware via adverse_events@beonemed.com and/or productcomplaints@beonemed.com.
 12. If attendees require proof of attendance to the Event, the Recipient is solely responsible for providing such proof and/or CPD education records, and shall comply with all applicable data privacy law requirements and necessary consents (and any transparency disclosures as contemplated under section 3 of this Agreement) to process such requests, including but not limited to ensuring the Event qualifies as a recognised course and is code compliant with the relevant medical association, where applicable.
 13. Recipient shall keep and maintain until ten (10) years after the Event have been completed full and accurate records relating to (i) the Event and the Support; (ii) all expenditure reimbursed by the Recipient; and (iii) all payments to any third party (HCPs included) made by the Recipient in connection with this Agreement. To ensure compliance with any applicable laws and regulations by Company, Recipient shall promptly on request afford Company or Company's representatives' access to all records relating to (i), (ii) and (iii) above at Company's expenses. Such records shall be made available to Company during normal business hours at the Recipient's office or place of business or, in the event that no such location is reasonably available, via email.
 14. The Parties will process all personal data (as defined in applicable data protection laws) obtained during the course of the Event in accordance with the applicable data protection laws.

Company will only process any personal data received from the Recipient in order to enter into or perform this Agreement. Recipient warrants that it shall limit the personal data disclosed to Company to the contact information for individuals involved with this Agreement and shall inform or obtain the prior written consent of each individual, as required by applicable law, for the disclosure of their respective personal data to Company and processing in accordance with this clause. The parties understand that Company will not have any further information/consent obligations towards the Recipient's personnel.
 15. This Agreement shall commence on the Effective Date and shall automatically terminate two (2) months from the date of the completion of the Event.

CONFIDENTIAL

16. In the event of a conflict between the provisions in the main body of this Agreement and any annex or attachment hereto, the provisions of this Agreement will control.
17. The parties agree that this Agreement will be governed by and interpreted under the laws of Denmark. Any dispute arising out of this Agreement shall be submitted to the exclusive jurisdiction of the competent courts of Copenhagen, Denmark.
18. This Agreement may be executed in counterparts all of which taken together shall constitute one agreement and copies may be exchanged electronically, such as by e-mail (e.g. PDF) and such electronic copy of the signed document will be considered valid and binding on the signing Party.

BeOne Medicines International GmbH Denmark Branch



AD5253FA6BBA4BE...

Name : Carl Gustav Fabiansson

Title: Senior Director, Country Manager Nordics

Date: 24-Oct-2025

Patientforeningen Lungekræft


4AE9474995FF407...

Name : Lisbeth Søbæk Hansen

Title: Formand

Date: 26-okt-2025

Annex 1 - Original Request for Support/Sponsorship Benefits

Beigene Nordics
Att. Casper Nilsson

D 6 juli 2025

Ansøgning om økonomisk støtte til International Lungekræftdag

Patientforeningen Lungekræft ønsker at ansøge Beigene Nordics om økonomisk støtte til International Lungekræftdag den 17. november 2025 som afholdes i København.

På dagen har vi inviteret læger, fagpersonale, politikere samt andre til at komme og holde indlæg på dagen samt til at deltage i en debat. Foreløbigt program for dagen vedlægges

På dagen er patienter, pårørende, politikere samt andre der har interesse for lungekræft inviteret til dagen

På dagen forventer vi at der vil deltage mellem 100 – 140 personer.

Budget for dagen:

Leje af kongressalen – IDA Mødecenter incl. teknisk assistance	Kr. 44.575,00
Forplejning morgenmad med wienerbrød	Kr. 8.750,00
Frokost incl. en vand	Kr. 35.625,00
Eftermiddagskaffe incl. kage og frug	Kr. 19.375,00
PR / invitationer / bnef af oplægsholder	Kr. 37.500,00
Tryk af invitationer samt port	Kr. 10.000,00
Moderator Lene Johansen	Kr. 35.000,00
I alt	Kr.190.825,00

Patientforeningen Lungekræft
Nørretorv 30, 2. sal
4100 Ringsted

Tlf. 4016 2335
info@lungekraeft.com
www.lungekraeft.com

Annex 2 – Agenda

INVITATION TIL

INTERNATIONAL LUNGEKRÆFTDAG 2025

København, mandag den 17. november, kl. 10.00-15.00 2025
IDA Mødeceter, Kalvebod Brygge 31-33, 1780 København V.

LIVET MED LUNGEKRÆFT – FRA DIAGNOSE TIL HVERDAG

Hvordan er det at leve med lungekræft i Danmark i 2025? Det spørgsmål danner rammen for årets Internationale Lungekræftdag.

Lungekræft er en alvorlig sygdom, der ikke kun påvirker kroppen, men også hverdagen, relationer og fremtidsudsigter for både patienter og pårørende. Med årets tema "Livet med lungekræft: fra diagnose til hverdag" sætter vi fokus på hele patientforløbet - fra de første symptomer til diagnosticering, behandling og livet både undervejs og bagefter.

Dagen byder på oplæg og samtaler om tidlig opsporing, kost og ernæring, mental trivsel, livskvalitet og fremtidens behandlingsmuligheder - samt de politiske visioner i Kræftplan V. Dagen rundes af med en brevkasse-session, hvor oplægsholdere fra dagen besvarer spørgsmål fra deltagerne. Du er også meget velkommen til at sende spørgsmål til Patientforeningen Lungekræft inden dagen.

Konferencen samler patienter, pårørende, klinikere, forskere og politikere til en fælles samtale om at leve med - og leve godt med - lungekræft.

Vi glæder os til en dag med viden, perspektiv og håb - og til at byde dig velkommen til International Lungekræftdag 2025!



Patientforeningen
Lungekræft



MODERATOR:
LENE JOHANSEN (JOURNALIST)

PROGRAM

09:30-10:00 Ankomst, registrering og kaffe/the

10:00-10:15 Velkomst og åbningstale
v. Lisbeth Søbæk Hansen, formand for Patientforeningen Lungekræft

10:15-10:35 Kræftplan V og de politiske visioner for lungekræftbehandlingen
v. Jesper Fisker, adm. direktør, Kræftens Bekæmpelse

10:35-11:05 Opsporing og tidlig diagnostik – hvordan opdager vi lungekræft i tide?
Samtale mellem lungemediciner og praktiserende læger om samarbejde, ansvar og muligheder for at styrke den tidlige diagnostik.
v. Uffe Bødtker, Forskningsleder i Forskningsenheden PLUZ, overlæge, PhD, professor i Lungemedicin, Sjællands Universitetshospital og Syddansk Universitet
Dorte Ejg Jørbøl, professor og speciallæge i almen medicin, ph.d., Forskningsenheden for Almen Praksis, Syddansk Universitet
Lisa Maria Sele Sætre, læge, ph.d., Forskningsenheden for Almen Praksis, Syddansk Universitet

11:05-11:25 Kvinder og lungekræft – en overset udfordring
v. Susanne Oksbjerg Dalton, professor, Københavns Universitet og Forskningsleder i Dansk Forskningscenter for Lighed i Kræft (COMPAS), Sjællands Universitetshospital

11:25-11:45 Mental sundhed og livskvalitet hos patienter med lungekræft
v. Elisabeth Rokkjær Hammer, Cand. Teol., Master i Sjælesorg, Hospitalspræst ved Palliativ Team og Børne og Unge Palliativ Team, Odense Universitetshospital



Patientforeningen Lungekræft
- et uafhængigt netværk for lungekræftpatienter og pårørende

- Vi arbejder for at forbedre forholdene for lungekræfttramte
- Vi deltager i den offentlige debat om lungekræft og sygdommens følger/indvirkninger
- Vi støtter og vejleder lungekræfttramte og deres pårørende

**INTERNATIONAL
LUNGEKRÆFTDAG 2025**

11:45-12:05 Fremtidens lungekræftbehandling – hvad sker der med de medicinske fremskridt indenfor behandlingen af lungekræft?
v. Jon Lykkegaard Andersen, overlæge, Onkologisk Afdeling, Herlev og Gentofte Hospital

12:05-13:15 Frokost, netværk og kaffe/kage

13:15-13:35 Kost og ernæring hos patienter med lungekræft – hvorfor er det så vigtigt?
v. Mette Theil, klinisk diætist, formand af Fagligt selskab Af Kliniske Diætister i Kost og Ernæringsforbundet

13:35-14:25 Paneldebat: Livet med lungekræft – fra politiske visioner til hverdagsliv
Hvordan lever man godt med lungekræft – og hvordan kan Kræftplan V bidrage til det? Politikere, klinikere og patienter drøfter, hvordan vi omsætter sundhedspolitiske visioner til konkret handling i hverdagen. Debatten sætter fokus på både behandling, opfølgning og livet under og efter sygdom – herunder tidlig opsporing, almen praksis og lighed i adgang til hjælp og støtte.

Paneldeltagere:

Jesper Fisker	Susanne Oksbjerg Dalton
Uffe Bødger	Mette Theil
Dorte Ejg Jarbøl	Jon Lykkegaard
Lisa Maria Seife Sætre	Lisbeth Sobæk Hansen

14:25-14:45 Brevkassen – spørgsmål fra publikum
Moderator styrer samtalen, hvor oplægsholdere fra dagen svarer på spørgsmål – også dem, der er stillet anonymt på forhånd. Du er velkommen til at sende dit spørgsmål til Lisbeth Sobæk Hansen (info@lungekraeft.com) – gerne inden d. 10. november 2025.

14:45-15:00 Afrunding og tak for i dag

Vi bliver endnu stærkere med dit medlemskab som:

- Patient
- Pårørende
- Støttemedlem
- Virksomhed

Læs mere og
meld dig in d på:
lungekraeft.com



INVITATION TIL INTERNATIONAL LUNGEKRÆFTDAG 2025



PRAKTISKE OPLYSNINGER

 **Arrangør:**
Patientforeningen Lungkræft

 **Tid:**
Mandag den 17. november 2025, kl. 09.30-15.00 2025

 **Sted:**
IDA Mødeceter, Kalvebod Brygge 31-33, 1780 København V.

 **Tilmelding:**
Senest den 1. november 2025 til Lisbeth Søbæk Hansen på mail info@lungekraeft.com eller telefon 40 16 23 35

Deltagelse i konferencen er gratis, men ved udeblivelse eller afbud efter den 10. november 2025 opkræves et gebyr på 300 kr.

Konferencen er for lungkræftframte og deres pårørende samt alle, der interesserer sig for at forbedre forholdene for lungkræftpatienter og behandlingen af lungkræft - herunder læger, sygeplejersker, andre sundhedsfaglige, sundhedspolitikere, forskningsinstitutioner og lægemiddelvirksomheder.

 Patientforeningen Lungkræft

Patientforeningen Lungkræft
Nørstov 30, 2. sal
4100 Ringsted

TH: 40 16 23 35
Mail: info@lungekraeft.com
www.lungekraeft.com

Certifikat for færdiggørelse

Kuvert-id: 8F50CA10-2F68-43B2-B457-FCD20206F0E4

Status: Gennemført

Emne: Patientforeningen Lungekræft_Sponsorship/Grant/Donation_ID 149807

Kildekuvert:

Dokumentsider: 9

Underskrifter: 2

Kuvertskaber:

Certifikatsider: 5

Initialer: 0

svc.Agiloft DocuSign

Autonavagation: Aktiveret

55 Cambridge Parkway

Kuvertstempling: Aktiveret

Suite 700W

Tidszone: (UTC-08:00) Pacific Time (US & Canada)

Cambridge, MA 02142

svc.AgiloftDocuSign@beigene.com

IP-adresse: 54.222.243.178

Sporing af poster

Status: Original

Ihændeher: svc.Agiloft DocuSign

Sted: DocuSign

24-10-2025 06:06:22

svc.AgiloftDocuSign@beigene.com

Hændelser for underskriver

Underskrift

Tidsstempel

Carl-Gustav Fabiansson

DocuSigned by:

 AD5253FA6BB44BE...

Sendt: 24-10-2025 06:07:55

carl-gustav.fabiansson@beigene.com

Vist: 24-10-2025 06:15:18

Senior Director Country Manager Nordics

Signeret: 24-10-2025 06:15:25

BeOne Medicines Sweden AB

Vælg underskrift: Upload billede af underskrift

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

Brug af IP-adresse: 163.116.168.116

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 28-03-2023 04:20:14

Id: 851c041d-13b1-4ec6-9a71-51807dfc205f

Lisbeth Søbæk Hansen

Signed by:

 4AE9474995FF407...

Sendt: 24-10-2025 06:15:26

info@lungekraeft.com

Vist: 26-10-2025 14:33:23

Formand

Signeret: 26-10-2025 14:34:12

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse:

2001:2012:81b:5500:6537:9201:aaa6:67fb

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 26-10-2025 14:33:23

Id: 4d694b99-ab5a-47a4-9670-9f6bac2cac3c

Hændelser for personlig underskriver

Underskrift

Tidsstempel

Hændelser for redaktørlevering

Status

Tidsstempel

Hændelser for agentlevering

Status

Tidsstempel

Hændelser for midlertidig levering

Status

Tidsstempel

Hændelser for certificeret levering

Status

Tidsstempel

Hændelser for kopi (cc:)

Status

Tidsstempel

Marita Eriksson

Kopieret

Sendt: 26-10-2025 14:34:13

marita.eriksson@beigene.com

Vist: 26-10-2025 14:35:10

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via Docusign

Vidnehændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Notarhændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Hændelser for kuvertoversigt	Status	Tidsstempler
------------------------------	--------	--------------

Kuvert sendt	Med hash/krypteret	24-10-2025 06:07:55
Leveret certificeret	Sikkerhedskontrolleret	26-10-2025 14:33:23
Signering fuldført	Sikkerhedskontrolleret	26-10-2025 14:34:12
Gennemført	Sikkerhedskontrolleret	26-10-2025 14:34:13

Betalingshændelser	Status	Tidsstempler
--------------------	--------	--------------

Oplysninger om elektroniske poster og underskrifter

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, BeiGene Ltd (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact BeiGene Ltd:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: askit@beigene.com

To advise BeiGene Ltd of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at drinaldi@gizmofish.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from BeiGene Ltd

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to askit@beigene.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with BeiGene Ltd

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to askit@beigene.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify BeiGene Ltd as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by BeiGene Ltd during the course of your relationship with BeiGene Ltd.